Follow-on Biologics: Rep. Eshoo Revising Her Bill To Be Closer To Senate Provision
This article was originally published in The Pink Sheet Daily
Executive Summary
California Democrat drops data exclusivity to 12 years, plus six months for pediatric studies, and removes requirement for FDA guidance before approval.
You may also be interested in...
Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Trade associations representing largely brand manufacturers in the U.S. and Europe want FDA to release guidance on biosimilars before approving any applications, even though the law was written so the agency does not have to wait for guidance to conduct reviews.
Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Trade associations representing largely brand manufacturers in the U.S. and Europe want FDA to release guidance on biosimilars before approving any applications, even though the law was written so the agency does not have to wait for guidance to conduct reviews.
Follow-on Biologics Showdown In House Set For July 17
House tri-committee bill is silent on follow-on biologics, but Rep. Anna Eshoo wants to be heard. Can the germaneness rule save Rep. Waxman from defeat?